Fairvalue-Calculator Fairvalue-Calculator
EN DE

Jiangsu Sihuan Bioengineering Co (000518) Fair Value & Analysis

Healthcare · CN · Market cap 3.2B CNY

Price¥3.18
Fair Value¥1.46
Upside-54.1%
Quality88/100
Evidence: Medium Range ¥1.10 – ¥1.83

Analysis

Jiangsu Sihuan Bioengineering Co (000518) currently trades at ¥3.18, while our model-based Fair Value estimate is ¥1.46 — implying the stock looks roughly 54.1% overvalued today. We read business quality at 88/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).

About the company

Jiangsu Sihuan Bioengineering Co., Ltd., together with its subsidiaries, engages in the production and sales of biopharmaceutical products in China and internationally. The company offers Delusen and New Delusen, a human interleukin-2 for injection are immunomodulators used for the biotherapy of tumors and treatment of patients with weakened immune function; Xinlisheng, a human granulocyte colony-stimulating factor injection used to treat neutropenia caused by bone marrow transplantation, cancer chemotherapy, myelodysplastic syndrome, and aplastic anemia; and Huanerbo, a human erythropoietin injection used to treat symptoms, such as anemia caused by renal insufficiency. It is also involved in the provision of flower planting; forest and natural ecosystem management and protection; forest improvement; forestry product sales; Chinese herbal medicine planting; landscaping project construction; urban municipal greening management; scenic area management; municipal facilities management;…

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -32% Regeneron Pharmaceuticals, Inc (REGN) -4% UCB SA (UCB) -27% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -82%

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.